This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Uvidem

Takeda Pharmaceutical Company Ltd

Drug Names(s): IDD-3

Description: Uvidem is a therapeutic vaccine that consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.

Deal Structure: IDM and Sanofi-Aventis
In July 2001, IDM entered into an agreement with Sanofi-Aventis for the development and commercialization of up to 20 Cell Drugs over a 10-year period. For each Cell Drug for which Sanofi chooses to exercise the joint development option under the collaboration, IDM will receive milestone payments and reimbursement of certain expenses. In return, upon securing marketing approval for any Cell Drug developed under the collaboration, Sanofi will have a further option for an exclusive worldwide license to commercialize that product.

Sanofi has remaining options to participate in the clinical development of up to ten (or up to two per year) Cell Drugs through 2011. With respect to any Cell Drug Program, Sanofis option is exercisable at the beginning of clinical development of the product related to that program, following presentation by us to sanofi of a satisfactory development plan including proof of concept in vitro and safety in vivo.

One such...See full deal structure in Biomedtracker


Uvidem News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug